1. Scrip
  2. >>Business
  3. >>Deals

Surrozen Inks First Partnership With BI For Wnt-Targeted Retinopathy Candidate

 
• By Joseph Haas

German pharma takes global rights to preclinical bispecific antibody, while Surrozen will focus on Phase I candidates for inflammatory bowel disease and alcoholic hepatitis.

Surrozen deal
Surrozen inks first partnership based on new approach to targeting Wnt • Source: Shutterstock

Surrozen Inc. thinks it has found a way around some of the issues of targeting the Wnt receptor and hopes its partnership with Boehringer Ingelheim GmbH may demonstrate that its bispecific antibodies can provide regenerational benefit in retinopathy.

BI gets global rights to SZN-413, a preclinical candidate for retinal disease that has demonstrated an ability to yield normal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.